Benjamin F. Edwards & Company’s DexCom DXCM Stock Holding History

Benjamin F. Edwards & Company’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$18K	Buy	155 +4	+3%	+$506	﹤0.01%	1574
2024 Q1	$21K	Buy	151 +5	+3%	+$628	﹤0.01%	1514
2023 Q4	$18K	Buy	+146	New	+$14.9K	﹤0.01%	1504
2022 Q1	–	Sell	-276	Closed	-$37K	–	1771
2021 Q4	$37K	Buy	+276	New	+$39.7K	﹤0.01%	1108
2021 Q2	–	Sell	-24	Closed	-$2K	–	1699
2021 Q1	$2K	Hold	24	–	–	﹤0.01%	1612
2020 Q4	$2K	Sell	24 -2,576	-99%	-$230K	﹤0.01%	1524
2020 Q3	$268K	Buy	+2,600	New	+$272K	0.02%	523
2019 Q2	–	Sell	-276	Closed	-$8K	–	1920
2019 Q1	$8K	Sell	276 -248	-47%	-$8.71K	﹤0.01%	1369
2018 Q4	$16K	Buy	+524	New	+$16.6K	﹤0.01%	1148
2018 Q1	–	Sell	-1,600	Closed	-$23K	–	1619
2017 Q4	$23K	Hold	1,600	–	–	﹤0.01%	980
2017 Q3	$20K	Hold	1,600	–	–	﹤0.01%	984
2017 Q2	$29K	Hold	1,600	–	–	﹤0.01%	824
2017 Q1	$34K	Buy	1,600 +800	+100%	+$15.6K	0.01%	750
2016 Q4	$12K	Sell	800 -800	-50%	-$14.2K	﹤0.01%	896
2016 Q3	$35K	Buy	1,600 +400	+33%	+$8.9K	0.01%	611
2016 Q2	$24K	Hold	1,200	–	–	﹤0.01%	638
2016 Q1	$20K	Buy	+1,200	New	+$20K	﹤0.01%	673

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Benjamin F. Edwards & Company's DXCM Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its DexCom (DXCM) stake by 2.6% in Q2 2024, buying an estimated $506 and bringing the position to 155 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Benjamin F. Edwards & Company first reported a position in DXCM in Q1 2016 and has held it in 17 quarters since. The position peaked at $268K in Q3 2020. 1,000 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

Benjamin F. Edwards & Company held 155 shares of DexCom worth $18K as of Q2 2024.
Benjamin F. Edwards & Company bought 4 DexCom shares in Q2 2024, an estimated $506.
DexCom made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1574 holding.
Benjamin F. Edwards & Company first reported a position in DexCom in Q1 2016 and has held it in 17 quarters since.
Benjamin F. Edwards & Company's DexCom position peaked at $268K in Q3 2020.
1,000 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.